

WHAT IS CLAIMED IS:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding mitoNEET, wherein said antisense compound specifically hybridizes with and inhibits the expression of
5 mitoNEET.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein said antisense oligonucleotide comprises at least 8 contiguous nucleic acids of a nucleic
10 acid sequence of SEQ ID NO.1 – SEQ ID NO:617.
4. The antisense compound of claim 3 wherein said antisense oligonucleotide comprises a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:617.
5. The antisense compound of claim 2 wherein said antisense
15 oligonucleotide consists of at least 8 contiguous nucleic acids of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:617.
6. The antisense compound of claim 2 wherein said antisense oligonucleotide consists of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:617.
- 20 7. The antisense compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
8. The antisense compound of claim 1 or 7 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
9. The antisense compound of claim 1 or 7 wherein the antisense
25 oligonucleotide comprises at least one modified nucleobase.
10. The antisense compound of claim 8 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
11. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 30 12. A composition comprising the antisense compound of claim 7 and a pharmaceutically acceptable carrier or diluent.

13. A composition comprising the antisense compound of claim 8 and a pharmaceutically acceptable carrier or diluent.

14. A composition comprising the antisense compound of claim 9 and a pharmaceutically acceptable carrier or diluent.

5 15. A composition comprising the antisense compound of claim 10 and a pharmaceutically acceptable carrier or diluent.

16. A method of treating a human having a disease or condition associated with mitoNEET comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of mitoNEET is inhibited.

17. The method of claim 16 wherein the disease or condition is selected from diabetes, an immunological disorder, a cardiovascular disorder including hypertension, a neurologic disorder, and ischemia/reperfusion injury.

15 18. A method of treating a human having a disease or condition associated with mitoNEET comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 7 so that expression of mitoNEET is inhibited.

19. The method of claim 18 wherein the disease or condition is selected from diabetes, an immunological disorder, a cardiovascular disorder including hypertension, a neurologic disorder, and ischemia/reperfusion injury.

20 20. A method of treating a human having a disease or condition associated with mitoNEET comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 8 so that expression of mitoNEET is inhibited.

21. The method of claim 20 wherein the disease or condition is selected from diabetes, an immunological disorder, a cardiovascular disorder including hypertension, a neurologic disorder, and ischemia/reperfusion injury.

22. A method of treating a human having a disease or condition associated with mitoNEET comprising administering to said animal a

therapeutically or prophylactically effective amount of the antisense compound of claim 9 so that expression of mitoNEET is inhibited.

23. The method of claim 22 wherein the disease or condition is selected from diabetes, an immunological disorder, a cardiovascular disorder including hypertension, a neurologic disorder, and ischemia/reperfusion injury.

24. A method of treating a human having a disease or condition associated with mitoNEET comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 10 so that expression of mitoNEET is inhibited.

25. The method of claim 24 wherein the disease or condition is selected from diabetes, an immunological disorder, a cardiovascular disorder including hypertension, a neurologic disorder, and ischemia/reperfusion injury.